ArticleJournal of virology2024
A reporter Oropouche virus expressing ZsGreen from the M segment enables pathogenesis studies in mice.
Article in Journal of virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Emerging threat of Oropouche virus: Clinical features, experimental models, and virulence.Virulence · 2026Review
- NS-segment-based reporter influenza A viruses: engineering strategy, applications, and limitations.Journal of virology · 2026Review
- Oropouche virus causes acute hepatitis in mice controlled by type I interferons.Journal of virology · 2026Article
- Review
- Conserved pathogenesis of ancestral and contemporary Oropouche virus strains in a murine pregnancy model.Nature communications · 2026Article
- Oropouche virus causes acute hepatitis in mice controlled by Type I interferons.bioRxiv : the preprint server for biology · 2026Article
- Oropouche virus infects human neural progenitor cells and alters the growth of brain organoids.iScience · 2026Article
- Arrival of Oropouche Virus in a Nonendemic Area in Northeastern Brazil, 2024.Journal of medical virology · 2026Article
- Remdesivir as a potent antiviral against prototype and current epidemic Oropouche virus strains (BeAn19991 and PE-IAM4637).Virus research · 2026Article
- Preclinical Models of Oropouche Virus Infection and Disease.Pathogens (Basel, Switzerland) · 2025Review
- Phylogenomics and structural modelling feature accelerated evolution of Oropouche virus: 1955 to 2024.Virologica Sinica · 2025Article
- Oropouche virus efficiently replicates and is immunostimulatory in vivo in nonhuman primate species.Science advances · 2025Article
- Oropouche virus disrupts neurodevelopment and is vertically transmitted.Research square · 2025Article
- Mysterious Oropouche virus: Transmission, symptoms, and control.Infectious medicine · 2025Review
- Probing orthobunyavirus reassortment using Bunyamwera and Batai viruses as models.PLoS neglected tropical diseases · 2025Article
- Development of a HiBiT-tagged reporter Akabane virus and its application in antiviral drug screening.Frontiers in cellular and infection microbiology · 2025Article
- Oropouche Virus: An Emerging Orthobunyavirus.The Journal of general virology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Oropouche fever caused by Oropouche virus (OROV) is a significant zoonosis in Central and South America. Despite its public health significance, we lack high-throughput diagnostics, therapeutics, and a comprehensive knowledge of OROV biology. Reporter viruses are valuable tools to rapidly study virus dynamics and develop neutralization and antiviral screening assays. OROV is a tri-segmented bunyavirus, which makes generating a reporter virus challenging, as introducing foreign elements into the viral genome typically affects fitness. We previously demonstrated that the non-structural gene NSm on the OROV medium (M) segment is non-essential for replication
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.